Steven Leonard Chapman, the CEO and President of Natera, Inc. (NASDAQ:NTRA), recently sold 3,960 shares of the company's common stock. The transaction, which occurred on October 28, 2024, was executed at an average price of $118.21 per share, resulting in a total sale value of approximately $468,113.
Following this transaction, Chapman retains direct ownership of 189,762 shares in the company. According to a footnote in the filing, the sale was conducted to fulfill tax withholding obligations related to the vesting of restricted stock units (RSUs). This transaction was carried out under a pre-established trading plan designed to comply with Rule 10b5-1(c) under the Exchange Act.
In other recent news, Natera Inc . has been the subject of several analyst actions. Canaccord Genuity (TSX:CF) has maintained its Buy rating on the company, with an increased price target of $150, citing Natera's strong performance prospects. This decision was based on the company's potential updates to reimbursement and guidelines that may favor Natera's products, such as Panorama, Signatera, and its expanded carrier screening.
Natera has also secured a permanent injunction against NeoGenomics (NASDAQ:NEO)' RaDaR assay, asserting its patent rights within the genetic testing market. This development is part of Natera's broader efforts to protect its intellectual property rights within the genetic testing market.
Furthermore, analysts from Piper Sandler and TD (TSX:TD) Cowen have maintained their positive stances on Natera, reiterating their price targets and Buy ratings. Their confidence is based on the forthcoming Galaxy study results and Natera's presentation at the European Society for Medical Oncology conference.
Despite a delay in the submission of the ALTAIR study and the non-renewal of the Foundation Medicine partnership, Natera is projecting a 40% revenue growth compared to 2023, underscoring the company's commitment to growth and innovation in the personalized genetic testing and diagnostics space. These are among the recent developments that emphasize Natera's ongoing progress and potential in the genetic testing sector.
InvestingPro Insights
As Natera's CEO Steven Leonard Chapman sells shares to fulfill tax obligations, it's worth noting that the company's stock has shown remarkable performance. According to InvestingPro data, Natera has delivered a strong 221.08% return over the past year, with the stock trading near its 52-week high at 94.9% of that level. This performance aligns with the company's impressive revenue growth, which stood at 46.13% for the last twelve months as of Q2 2024.
Despite the positive momentum, InvestingPro Tips highlight that Natera is not currently profitable, with analysts not anticipating profitability this year. The company's P/E ratio of -53.66 for the last twelve months ending Q2 2024 reflects this lack of profitability. However, Natera operates with a moderate level of debt and its liquid assets exceed short-term obligations, suggesting a stable financial position.
For investors considering Natera, it's important to note that the stock price movements are quite volatile, as indicated by another InvestingPro Tip. This volatility, combined with the company's high Price/Book multiple of 18.74, suggests that investors should carefully consider their risk tolerance.
InvestingPro offers 12 additional tips for Natera, providing a more comprehensive analysis for those looking to delve deeper into the company's prospects. These insights can be particularly valuable given the company's complex financial picture, combining strong growth with current unprofitability.
Steven Leonard Chapman, the CEO and President of Natera, Inc. (NASDAQ:NTRA), recently sold 3,960 shares of the company's common stock. The transaction, which occurred on October 28, 2024, was executed at an average price of $118.21 per share, resulting in a total sale value of approximately $468,113.
Following this transaction, Chapman retains direct ownership of 189,762 shares in the company. According to a footnote in the filing, the sale was conducted to fulfill tax withholding obligations related to the vesting of restricted stock units (RSUs). This transaction was carried out under a pre-established trading plan designed to comply with Rule 10b5-1(c) under the Exchange Act.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.